BASEL--Novartis is understood to be conducting reviews of its PR support in both the consumer health and pharma divisions.
The consumer health process, according to sources, involves a focus on the company's roster of PR firms, and has seen a number of agencies submit proposals in Europe.
Novartis Consumer Health racked up sales of $3.7bn in 2012, covering the company's over-the-counter drugs and animal healthcare. Last year, Novartis' US unit recalled one of its best-known products, Excedrin, and has since extended the recall to Canada.
It has previously been reported that Novartis is seeking to raise global awareness of Excedrin.
Meanwhile, it is also understood that Novartis is seeking PR support for its multiple sclerosis pill Gilenya. The drug, which is available in both the US and EU, recently attained blockbuster status by generating sales of more than $1.2bn in 2012, after safety concerns threatened to derail its progress.
In the UK, healthcare firm Aurora has worked on Gilenya in the past.
"We regularly evaluate suppliers, but have made no decision to change our agency relationship at this time," said a Novartis spokesperson.